A 2026 review concluded that GLP-1 receptor agonists have plausible stroke biology and modest prevention signals, but current human evidence does not support routine use as acute ischemic stroke neuroprotection.1 The useful clinical split is prevention in cardiometabolic patients vs. acute brain-rescue treatment after stroke onset. Research Highlights Acute neuroprotection is not established: the 2026 …
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et al. propensity-matched 118,993 GLP-1 RA users to 118,993 non-users in the TriNetX network and found a modest but statistically robust 21–23% higher hazard of new-onset hypersomnolence at 1 and 5 years.1 …
A 2026 target-trial emulation involving 102,361 U.S. veterans with type 2 diabetes found no increased suicidality risk after starting semaglutide vs. sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors): suicidal ideation HR 0.99 and suicide attempt/death HR 1.05 after overlap weighting.1 That does not prove semaglutide prevents suicide, but it weakens the broad claim that semaglutide initiation itself …
GLP-1 drugs are usually described as appetite drugs, but a 2026 Nature mouse study mapped a more specific reward circuit: small-molecule GLP-1 receptor agonists suppressed palatable-food intake through Glp1r-expressing central-amygdala neurons that reduced dopamine release in the nucleus accumbens during high-fat-food retrieval.1 That mechanism makes binge-eating and substance-use hypotheses more plausible without turning an animal …
Semaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experiments. After 5 days of treatment, rats shifted away from cocaine choice without losing total operant responding, which separates the result from a broad appetite-suppression artifact. Research Highlights Semaglutide …
A 2026 Scientific Reports paper involving 1,205 participants found that people using GLP-1-style weight-loss medication were judged as less effortful, less moral, less competent, less warm, less deserving, and less attractive as cooperation partners after the same 20 kg weight loss described for a diet-and-exercise-only comparator. Research Highlights Same weight loss, harsher judgment: Tissot et …
Obesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between obesity, reduced brain volume and neuronal loss, increased dementia risk, and impaired learning, memory and cognition. Preliminary evidence suggests that weight loss drugs like semaglutide may …